Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles

English version České info

If future HIV vaccine design strategies are to succeed, improved understanding of the mechanisms underlying protection from infection or immune control over HIV replication remains essential. Increased cytotoxic capacity of HIV-specific CD8⁺ T-cells associated with efficient elimination of HIV-infected CD4⁺ T-cell targets has been shown to distinguish long-term nonprogressors (LTNP), patients with durable control over HIV replication, from those experiencing progressive disease. Here, measurements of granzyme B target cell activity and HIV-1-infected CD4⁺ T-cell elimination were applied for the first time to identify antiviral activities in recipients of a replication incompetent adenovirus serotype 5 (Ad5) HIV-1 recombinant vaccine and were compared with HIV-negative individuals and chronically infected patients, including a group of LTNP. We observed readily detectable HIV-specific CD8⁺ T-cell recall cytotoxic responses in vaccinees at a median of 331 days following the last immunization. The magnitude of these responses was not related to the number of vaccinations, nor did it correlate with the percentages of cytokine-secreting T-cells determined by ICS assays. Although the recall cytotoxic capacity of the CD8⁺ T-cells of the vaccinee group was significantly less than that of LTNP and overlapped with that of progressors, we observed significantly higher cytotoxic responses in vaccine recipients carrying the HLA class I alleles B*27, B*57 or B*58, which have been associated with immune control over HIV replication in chronic infection. These findings suggest protective HLA class I alleles might lead to better outcomes in both chronic infection and following immunization due to more efficient priming of HIV-specific CD8⁺ T-cell cytotoxic responses.

Vyšlo v časopise: Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles. PLoS Pathog 7(2): e32767. doi:10.1371/journal.ppat.1002002
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002002

Souhrn

Zdroje

1. MiguelesSAConnorsM 2010 Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 304 194 201

2. MiguelesSASabbaghianMSShupertWLBettinottiMPMarincolaFM 2000 HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97 2709 2714

3. LambotteOBoufassaFMadecYNguyenAGoujardC 2005 HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 41 1053 1056

4. BaileyJRWilliamsTMSilicianoRFBlanksonJN 2006 Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 203 1357 1369

5. Saez-CirionALacabaratzCLambotteOVermissePUrrutiaA 2007 HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 104 6776 6781

6. HanYLaiJBarditch-CrovoPGallantJEWilliamsTM 2008 The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. Aids 22 541 544

7. PereyraFAddoMMKaufmannDELiuYMiuraT 2008 Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197 563 571

8. MiguelesSAOsborneCMRoyceCComptonAAJoshiRP 2008 Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29 1009 1021

9. GoulderPJBunceMKrausaPMcIntyreKCrowleyS 1996 Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses 12 1691 1698

10. JagannathanPOsborneCMRoyceCManionMMTiltonJC 2009 Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. J Virol 83 2728 2742

11. YantLJFriedrichTCJohnsonRCMayGEManessNJ 2006 The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 80 5074 5077

12. LoffredoJTMaxwellJQiYGliddenCEBorchardtGJ 2007 Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 81 8827 8832

13. FriedrichTCValentineLEYantLJRakaszEGPiaskowskiSM 2007 Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol 81 3465 3476

14. Gea-BanaclocheJCMiguelesSAMartinoLShupertWLMcNeilAC 2000 Maintenance of large numbers of virus specific CD8+ T cells in HIV infected progressors and long term nonprogressors. J Immunol 165 1082 1092

15. BettsMRAmbrozakDRDouekDCBonhoefferSBrenchleyJM 2001 Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 75 11983 11991

16. AddoMMYuXGRathodACohenDEldridgeRL 2003 Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77 2081 2092

17. BettsMRNasonMCWestSMDe RosaSCMiguelesSA 2006 HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 4781 4789

18. ZimmerliSCHarariACelleraiCVallelianFBartPA 2005 HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 102 7239 7244

19. MiguelesSAWeeksKANouEBerkleyAMRoodJE 2009 Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 83 11876 11889

20. Lopez Bernaldo de QuirosJCShupertWLMcNeilACGea-BanaclocheJCFlaniganM 2000 Resistance to Replication of HIV Challenge Virus in SCID-Hu Mice Engrafted with PBMC of Nonprogressors is Mediated by CD8+ T cells and Associated with a Proliferative Response to p24 Antigen. Journal of Virology 74 2023 2028

21. MiguelesSALaboricoACShupertWLSabbaghianMSRabinR 2002 HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3 1061 1068

22. CatanzaroATKoupRARoedererMBailerRTEnamaME 2006 Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194 1638 1649

23. PriddyFHBrownDKublinJMonahanKWrightDP 2008 Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46 1769 1781

24. CasimiroDRWangFSchleifWALiangXZhangZQ 2005 Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79 15547 15555

25. ShiverJWFuTMChenLCasimiroDRDaviesME 2002 Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 331 335

26. BuchbinderSPMehrotraDVDuerrAFitzgeraldDWMoggR 2008 Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 1881 1893

27. McElrathMJDe RosaSCMoodieZDubeySKiersteadL 2008 HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372 1894 1905

28. KaslowRARiversCTangJBenderTJGoepfertPA 2001 Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 75 8681 8689

29. SmithWPVuQLiSSHansenJAZhaoLP 2006 Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes. Genomics 87 561 571

30. SachaJBChungCRakaszEGSpencerSPJonasAK 2007 Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 178 2746 2754

31. HortonHThomasEPStuckyJAFrankIMoodieZ 2007 Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 323 39 54

32. SpentzouABerginPGillDCheesemanHAshrafA 2010 Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis 201 720 729

33. FreelSALamoreauxLChattopadhyayPKSaundersKZarkowskyD 2010 Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 84 4998 5006

34. HortonHFrankIBaydoRJalbertEPennJ 2006 Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol 177 7406 7415

35. AltfeldMAddoMMRosenbergESHechtFMLeePK 2003 Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. Aids 17 2581 2591

36. LichterfeldMKaufmannDEYuXGMuiSKAddoMM 2004 Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 200 701 712

37. Rerks-NgarmSPitisuttithumPNitayaphanSKaewkungwalJChiuJ 2009 Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med

38. WuXYangZYLiYHogerkorpCMSchiefWR 2010 Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science

39. HansenSGVievilleCWhizinNCoyne-JohnsonLSiessDC 2009 Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15 293 299